DCAT Week in New York City is always an impactful gathering for the global biopharmaceutical manufacturing and supply chain ecosystem. For the Procegence team, DCAT Week 2026 was packed with high

A recurring theme across these conversations was a strong and growing sense of urgency to accelerate scale‑up, technology transfer, and time‑to‑market. Many organizations are navigating increasingly complex and diverse pipelines, tighter development timelines, and higher expectations for robustness and reliability as programs transition from clinical development toward commercial manufacturing. Companies are being asked to move faster while managing risk more deliberately, often across multiple sites and partners.

What stood out this year was the level of interest in modeling and simulation (M&S) as a practical, decision‑enabling capability, rather than a purely academic or exploratory exercise. Several organizations expressed a clear need for M&S approaches that can support rapid scale‑up, de‑risk technology transfer, and improve early process understanding, especially when experimental data are limited or extensive trial‑and‑error experimentation isn’t possible due to timeline constraints. These discussions highlighted a shift toward using models earlier and more proactively to inform development strategy.

The conversations reinforced how mechanistic and hybrid modeling, when applied pragmatically and integrated into development workflows, can help organizations shorten development cycles, improve cross‑site and cross‑partner alignment, and make more confident, data‑informed decisions - ultimately supporting faster, more reliable paths to market.

DCAT Week once again proved the value of focused, in‑person engagement and strategic dialogue, and underscored the industry’s continued momentum toward smarter, model‑enabled development and manufacturing.

Learn more from Procegence and how we can help your team get started with M&S.